High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies

International Journal of Cancer

Volumn 124, Issue 2, 2009, Pages 333-338

  Tinari, Nicola ^a   Lattanzio, Rossano ^a   Querzoli, Patrizia ^b   Natoli, Clara ^a   Grassadonia, Antonino ^a   Alberti, Saverio ^a   Hubalek, Michael ^c   Reimer, Daniel ^c   Nenci, Italo ^b   Bruzzi, Paolo ^d   Piantelli, Mauro ^a   Iacobelli, Stefano ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

90K; Breast cancer; Prognosis

Indexed keywords

ONCOPROTEIN; PROTEIN 90K; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; TAA90K PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; BIOLOGICAL MODEL; BREAST TUMOR; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PHYSIOLOGY; RISK; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; AGED; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK; TREATMENT OUTCOME;

EID: 58249091144     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23970     Document Type: Article

References (34)

1. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004;9:606-16.
2. Tyczynski JE, Bray F, Parkin DM. Breast cancer in Europe. ENCR Cancer Fact Sheets 2002;2:1-4.
3. Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 2003; 39:1718-29.
4. Peto R, Borerham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in 2000 at ages 20-69 years. Lancet 2000;355:1822.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687-717.
6. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-83.
7. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ, Jr, Deshler A, Fulton S, Hendricks CB, Kemeny M, Kornblith AB, Louis TA, Markman M, et al. National Institute of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, Nov 1-3, 2000. J Natl Cancer Inst 2001;93:979-89.
8. Bast RC, Jr, Ravdin P, Hayes DF, Bates S, Fritsche H, Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR; American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
9. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-84.
10. Iacobelli S, Arno E, D'Orazio A, Colletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 1986;46:3005-10.
11. Iacobelli S, Arno E, Sismondi P, Natoli C, Gentiloni N, Scambia G, Giai M, Cortese P, Panici PB, Mancuso S. Measurement of breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. Breast Cancer Res Treat 1988;11:19-30.
12. Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S. Mac-2-binding glycoproteins. Putative ligands for cytosolic β-galactoside lectin. J Biol Chem 1991;266:18731-36.
13. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2 binding protein a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem 1993;268:14245-49.
14. Inohara H, Akahani S, Kohts K, Raz A. Interactions between galectin- 3 and Mac-2 binding protein mediate cell-cell adhesion. Cancer Res 1996;56:4530-34.
15. Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT. Glycoprotein 90K/Mac-2BP interacts with galectin-1 and mediates galectin-1 induced cell aggregation. Int J Cancer 2001;91:167-72.
16. Sasaki T, Brakebusch C, Engel J, Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds β1 integrins, collagens and fibronectin. EMBOJ 1998;17:1606-13.
17. Fornarini B, D'Ambrosio C, Natoli C, Tinari N, Silingardi V, Iacobelli S. Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood 2000;96:3282-85.
18. Iacobelli S, Sismondi P, Giai M, D'Egidio M, Tinari N, Amatetti C, Di Stefano P, Natoli C. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer 1994;69:172-6.
19. Zhang DS, Ding Y, Li YH, Xu RH, Wang B, Zhang XS, Zeng J, Liang HZ, Jiang WQ. Expression of glycoprotein 90K in non-Hodgkin's lymphoma and its clinical significance. Ai Zheng 2005;24: 1006-10.
20. Iacovazzi PA, Guerra V, Elba S, Sportelli F, Manghisi OG, Correale M. Are 90K/MAC-2BP serum levels correlated with poor prognosis in HCC patients? Preliminary results. Int J Biol Markers 2003;18: 222-6.
21. Strizzi L, Muraro R, Vianale G, Natoli C, Talone L, Catalano A, Mutti L, Tassi G, Procopio A. Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. J Pathol 2002;197:218-23.
22. Gentiloni N, Caradonna P, Costamagna G, D'Ostilio N, Perri V, Mutignani M, Febbraro S, Tinari N, Iacobelli S, Natoli C. Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. Am J Gastroenterol 1995;90:1069-72.
23. Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti CA, Sacco R, Mucilli F, Ullrich A, Iacobelli S. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 2002;62:2535 - 39.
24. Tinari N, D'Egidio M, Iacobelli S, Bowen M, Starling G, Seachord C, Darveau R, Aruffo A. Identification of the tumor antigen 90K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90K monoclonal antibodies. Biochem Biophys Res Commun 1997;232:367-72.
25. Clark GM. Interpreting and integrating risk factors for patients with primary breast cancer. J Natl Cancer Inst Monogr 2001;30:17-21.
26. Fidler IJ. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst 1970;45:773-82.
27. Jallal B, Powell J, Zachwieja J, Brakebusch C, Germain L, Jacobs J, Iacobelli S, Ullrich A. Suppression of tumor growth in vivo by local and systemic 90K level increase. Cancer Res 1995;55:3223-7.
28. Powell TJ, Schreck R, McCall M, Hui T, Rice A, App H, Azam M, Ullrich A, Shawver LK. A tumor-derived protein which provides T- cell costimulation through accessory cell activation. J Immunother Emphasis Tumour Immunol. 1995;17:209-21.
29. Gangopadhyay A, Lazure DA, Thomas P. Adhesion of colorectal carcinoma cells to the endothelium is mediated by cytokines from CEA stimulated Kupffer cells. Clin Exp Metastasis 1998;16:703-12.
30. Ozaki Y, Kontani K, Teramoto K, Fujita T, Tezuka N, Sawai S, Maeda T, Watanabe H, Fujino S, Asai T, Ohkubo I. Involvement of 90K/Mac-2 binding protein in cancer metastases by increased cellular adhesiveness in lung cancer. Oncol Rep 2004;12:1071-7.
31. Bair EL, Nagle RB, Ulmer TA, Laferté S, Bowden GT. 90K/Mac-2 binding protein is expressed in prostate cancer and induces promatrilysin expression. Prostate 2006;66:283-93.
32. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, Shawverll LK, Schlessinger J, et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. J. Biol Chem 1994;269:18401-7.
33. Lee JH, Cho ES, Kim MY, Seo YW, Kho DH, Chung IJ, Kook H, Kim NS, Ahn KY, Kim KK. Suppression of progression and metastasis of established colon tumors in mice by intravenous delivery of short interfering RNA targeting kitenin, a metastasis-enhancing protein. Cancer Res 2005;65:8993-9003.
34. Ulmer TA, Keeler V, Loh L, Chibbar R, Torlakovic E, André S, Gabius HJ, Laferte S. Tumor-associated antigen 90K/Mac-2-binding protein: possible role in colon cancer. J Cell Biochem 2006;98:1351-66.